CARCINOMA, HEPATOCELLULAR

This study tested whether adding a third drug (relatlimab) to a standard two-drug treatment (nivolumab and bevacizumab) is safe and more effective for people with untreated advanced liver cancer. It involved 83 participants who were randomly assigned to receive either the three-d…

This large, completed Phase 3 trial tested whether adding the immunotherapy drug pembrolizumab to the standard drug lenvatinib works better for adults with advanced liver cancer. The main goal was to see if the combination helps patients live longer without their cancer getting w…

This study tested whether adding the drug pembrolizumab to standard supportive care helped Asian patients with advanced liver cancer live longer. It involved 453 people whose cancer had worsened after their first treatment. Participants were randomly assigned to receive either th…

This study tested whether giving patients with operable liver cancer a short course of immune-boosting drug combinations before surgery could help shrink their tumors. The goal was to see if this 'neoadjuvant' approach could lead to better surgical outcomes and lower the chance o…

This study tested the safety and effectiveness of a new drug, E7386, combined with an existing immunotherapy (pembrolizumab) for people with advanced melanoma, liver cancer, or colorectal cancer that had worsened after prior treatments. The first part checked for side effects and…

This study tested the safety and effectiveness of a two-drug combination (atezolizumab and bevacizumab) for patients with advanced liver cancer that cannot be removed by surgery. It involved 152 patients who had not received any prior drug treatment for their cancer. The main goa…